Chitosan Compounds Enhancing Antibody Binding for Infection Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating infections caused by viruses and bacteria, such as COVID-19, lack effective alternatives for enhancing virus-neutralizing antibody binding and detection, particularly in providing sustained protection and easy administration.
Innovation Solution
The use of chitosan or its salts, galactose, mannose, caffeine, or combinations thereof, to increase the binding of virus-neutralizing antibodies and facilitate the detection of virus-specific antibodies by contacting them with a fluid containing viruses, and their application in compositions for preventing infections, treating diseases, and as a chewing gum for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used for preventing and treating viral infections, then basic protection is provided, but effective enhancement of virus-neutralizing antibody binding and detection is not achieved
Solution Approach 1:
The patent introduces chitosan and its derivatives as intermediary substances that mediate between virus-neutralizing antibodies and viral proteins. These compounds enhance the binding interaction by acting as a bridge, thereby improving both the effectiveness of antibody binding and the sensitivity of detection methods without requiring fundamental changes to existing therapeutic or diagnostic approaches.
Solution Approach 2:
The patent modifies the chemical and physical parameters of the antibody-virus interaction system by introducing chitosan compounds with specific molecular weights, degrees of deacetylation, and functional group compositions. These parameter changes enhance binding affinity and detection sensitivity while maintaining compatibility with existing medical and diagnostic protocols.
2Reliability
If complex treatment compositions are used to enhance antibody binding, then binding effectiveness is improved, but ease of administration and sustained protection are compromised
Solution Approach 1:
The patent optimizes key parameters of chitosan compounds including molecular weight (1,000-1,000,000 Da), degree of deacetylation (20-100%), and functional group composition to achieve enhanced binding effectiveness while maintaining solubility, stability, and ease of administration. These parameter optimizations allow the compounds to be formulated in various dosage forms suitable for different administration routes.
Solution Approach 2:
The chitosan compounds described in the patent serve multiple functions simultaneously: they enhance antibody binding to viral proteins, provide sustained protection through prolonged residence time, facilitate detection of virus-specific antibodies, and can be administered through multiple routes (oral, nasal, inhalation). This multi-functionality eliminates the need for complex combination therapies.
3Difficulty of detecting and measuring
If conventional detection methods are used for virus-specific antibodies, then basic detection is achieved, but sensitivity and accuracy are limited
Solution Approach 1:
The patent employs chitosan compounds as intermediary substances in detection assays, where they facilitate the interaction between virus-specific antibodies and viral proteins or peptides. This intermediary approach enhances the sensitivity and accuracy of detection by improving signal generation and reducing background noise, while maintaining compatibility with conventional ELISA and other standard diagnostic platforms.
Solution Approach 2:
The patent optimizes detection assay parameters by introducing chitosan compounds with specific molecular characteristics that enhance antibody binding affinity and signal amplification. These parameter changes include adjusting chitosan concentration, molecular weight, and functional group composition to maximize detection sensitivity while maintaining assay specificity and reducing false positives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the binding of virus-neutralizing antibodies, aids in the detection of virus-specific antibodies, and provides a sustainable method for preventing infections by inhibiting viral entry into host cells, offering a potential treatment for diseases like COVID-19 through various administration routes.
Implementation Method 1
contacting a fluid that contains a virus and virus neutralizing antibodies, wherein the virus neutralizing antibodies bind to said virus, with a compound selected from the group consisting of chitosan or a salt thereof, galactose, mannose, caffeine, and any combination thereof
Implementation Method 2
contacting a fluid that contains virus-specific antibodies with virus protein under conditions that allow binding of the virus-specific antibody to the virus protein, with a compound selected from the group consisting of chitosan or a salt thereof, galactose, mannose, caffeine, and any combination thereof, thereby detecting said virus-specific antibodies
Data Source
AI summary
Compounds and compositions, their use and methods using the compounds and compositions for preventing an infection, e.g. an infection by a virus or bacterium, or treating an infection, e.g. a virus or bacterial infection, or treating a disease caused by an infection, e.g. a virus or bacterial infection, and a method of increasing the binding of virus neutralizing antibodies, an in vitro method of detecting virus-specific antibodies in a sample obtained from a subject, a compound for use in a method of detecting of virus-specific antibodies in a subject, and a kit for the detection of virus-specific antibodies.